Vericel Reports Third Quarter 2024 Financial Results
Portfolio Pulse from
Vericel Corporation reported a strong third quarter for 2024 with a 27% increase in total revenue to $57.9 million, a gross margin of 72%, and an 84% growth in adjusted EBITDA. The company raised its full-year profitability guidance following the FDA approval and commercial launch of MACI Arthro.
November 07, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vericel Corporation reported a 27% increase in revenue and an 84% growth in adjusted EBITDA for Q3 2024. The company also raised its full-year profitability guidance following the FDA approval and launch of MACI Arthro.
The significant revenue and EBITDA growth, along with the FDA approval and launch of a new product, are positive indicators for Vericel's financial health and future prospects. This is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100